From CFTR modulators to gene therapy, what's next in cystic fibrosis research? Peter Mogayzel examines future therapies, ongoing access challenges, and the crucial link between advocacy, innovation, and global health equity in cystic fibrosis care.

Timestamps:

00:00 – Introduction

01:05 - CFTR modulators

03:35 – Anti-inflammatory drugs

04:18 – mRNA therapy

04:53 – Side effects

07:13 – Access to care

08:37 – Exercise

10:00 – Final thoughts

What defines excellence in cystic fibrosis clinical care? Peter Mogayzel discusses the latest therapeutic guidelines, managing pulmonary exacerbations, the role of home monitoring, and how multidisciplinary teams work together to support patients in leading full, active lives.

Timestamps:

00:00 – Introduction

00:41 – Key guidelines

01:54 – Multisystem disease

02:32 – Pulmonary exacerbations

04:04 – Chronic medications

05:37 – Home monitoring

08:15 – Multidisciplinary care

How did the USA build one of the world's most comprehensive cystic fibrosis care systems? In Part 1 of our deep dive, Peter Mogayzel explores the development of national cystic fibrosis centres, the impact of newborn screening, and how a strong foundation in care standards transformed outcomes across generations.

Timestamps:

00:00 – Introduction

01:38 – Care models

02:40 – Early screening

04:20 – CF Foundation

05:33 – What's changed?

In this quickfire introduction, Peter J. Mogayzel answers fast questions about the evolution of cystic fibrosis care in the USA, from early screening and survival milestones to innovation, policy, and equitable access. A perfect primer on where cystic fibrosis care stands today.

In the second episode of this three-part series, we delve into the science behind Refractory Chronic Cough (RCC), focusing on the role of neuronal hypersensitivity and how the cough reflex becomes dysregulated.1 Join leading experts as they explain the neurobiology of RCC, discuss the latest research, and share practical insights for identifying RCC in clinical practice.